Institute for Cell and Molecular Biosciences

Staff Profile

Professor Nick Reynolds




BSc Hons (Intercalated) University of London, 1980
MBBS University of London, 1983
MD University of London, 1995
FRCP, Royal College of Physicians, London, 1999

Previous Positions

2001-present Professor of Dermatology, University of Newcastle upon Tyne
2001-2004 Wellcome Trust Research Leave Fellowship for Clinical Academics
1995-2001 Senior Lecturer, University of Newcastle upon Tyne and
Consultant Dermatologist, Royal Victoria Infirmary, Newcastle upon Tyne
1993-1994 Senior Registrar, Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne
1990-1992 Research Fellow and Lecturer, Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA
1987-1990 Registrar, Department of Dermatology, Bristol Royal Infirmary, Avon

Roles and Responsibilities 

Honorary Consultant Dermatologist, Newcastle upon Tyne Hospitals NHS Foundation Trust
2008 - 2015 Board Member,  European Society for Dermatological Research (ESDR)
2011 - Chair, Research Committee, British Association of Dermatologists Biologic Interventions Register (BADBIR)
2012 - Chair, UK Translational Research Network in Dermatology (UK TREND)
2013-2014 - President, European Society for Dermatological Research (ESDR)


Research Interests

• Translational and systems biology research in dermatology and skin biology (including Proximity to Discovery scheme)
• Stratified medicine in Psoriasis and mechanism of action of anti-psoriatic drugs (PSORT:;
• Keratinocyte cell signalling
• UV and wound healing signalling responses
• Clinical trials, molecular genetics and disease models of atopic eczema

My laboratory is interested translatonal research of inflammatory skin disease (specifically psoriasis and atopic eczema).  We have a particular interest in gaining insights into disease mechanisms and the pathways involved in clearing psoriasis.  We are part of a consortium led by the University of Manchester that has begun work to apply a stratified medicine approach to psoriasis and predict which biological therapy is best suited for an individual patient.  The Psoriasis Stratification to Optimise Relevant Therapy (PSORT) consortium is a unique partnership between five UK universities: Manchester, Newcastle, King’s College London, Queen Mary and Liverpool, 10 pharmaceutical and diagnostics companies and the Psoriasis Association and NHS partners representing patients.

We also study the mechanism of action of anti-psoriatic therapies including UVR as we think this may provide important insights into disease pathogenesis and lead to the identification of new therapeutic targets. On-going studies focus on the induction of apoptosis by UVR in the clearance of psoriatic plaques, the interaction of calcineurin inhibitors (ciclosporin and tacrolimus) with the Ca2+/calcineurin/NFAT pathway in human keratinocytes, and the role of mitochondria in mediating the therapeutic action of dithranol in psoriasis.

Another area of focus is keratinocyte cell signalling, particularly in response to environmental insults such as ultraviolet radiation, wounding (in collaboration with Prof Jeremy Lakey, through a EPSRC/BBSRC Innovate UK project) and AhR receptor activation (through a BBSRC Case studentship with Astra Zeneca). We are interested in understanding the regulation of diverse cellular responses induced by UVR. These studies are supported by important collaborations with Professor Peter Farr and Dr Sophie Weatherhead, Dermatology RVI.

We have conducted important investigator-led clinical trials in atopic eczema (e.g. REF 2014 impact case - graded at least 3* - internationally excellent) and have contributed to increased understanding of the molecular genetics of atopic eczema. We have set up a skin equivalent model of atopic eczema which we are using to investigate therapeutic targets ((through a BBSRC Case studentship with Stiefel/GSK).

I am also lead investigator of Newcastle’s Proximity to Discovery scheme.  Newcastle University was the only institution in the UK to be awarded the highest amount - £250,000 in 2014 by the Medical Research Council underscoring our strengths in translational research, business development & innovation and stratified medicine.   Our 2015 application was also recently renewed.  The goal of the Newcastle Proximity to Discovery programme is to address, in a systematic and innovative fashion - the so called ‘third translational gap’, that is the bilateral knowledge gap between Universities and industry, in order to build further joint ventures and projects.

Research Group Members

Dr Keith Wu, NIHR Lecturer

Emma Woodward, PhD student (submitted)

Martina Elias, PhD student (submitted)

Carole Todd, Senior Research Technician

Dr Emma Burton, PSORT project manager

Dr Graham Smith, PSORT post-doctoral systems biologist

PSORT technician, to be appointed

Rosetrees technician. to be appointed

Dr Robbie Samuel, NIHR academic foundation fellow

Dr Henry Graham, NIHR academic foundation fellow

Postgraduate Supervision



BBSRC (CASE) with AstraZeneca and GSK
Biomedical Research Centre (BRC) 

British Skin Foundation


Rosetrees Foundation



We place a strong emphasis on undergraduate teaching and postgraduate training.  We run an active weekly programme both within ICM and dermatology (clinical and basic science journal clubs, research in progress meetings) and play a key role in the MRes in Medical and Molecular Biosciences

Many of our clinical trainees pursue higher research degrees funded through external nationally funded fellowships (Wellcome, MRC, Action Medical Research, British Skin foundation) and our PhD students have secured fellowships (European Commission) and post-doctoral positions  (eg Settembre lab, TIGEM, Pozzuoli, Italy; Khavari lab, Stanford; Buck Institute, San Francisco; NIH, Bethesda; University of Chicago).  In 2006/2007, we were one of only three units in England and Wales to be awarded academic clinical fellowships in dermatology through a national competition and a Walport/NIHR Lectureship was recently established.

Since 2008, three of our clinical trainees have gone on to secure prestigious Wellcome Intermediate Fellowships, one in Dundee and two in Newcastle.  Two of these investigators were recently awarded Senior Wellcome Fellowships in Clinical Science (one in Dundee and one in Newcastle).

Postgraduate Student Supervision - Current

Martina Elias (PhD)(submitted)*

Emma Woodward (PhD)(submitted)*

Postgraduate Student Supervision - Completed

Keith Wu (PhD)

Laura Hudson PhD, 2014

Aparna Sinha MD, 2014*

Darren Johnson PhD, 2013*

Nicola Fullard PhD, 2013

Alison Forrester PhD, 2012*

Sophie Weatherhead PhD, 2011*

Shanji Anthony MPhil, 2009*

Sarah Milner PhD, 2009*

Baba Taal PhD, 2009*

Sara Brown MD with commendation, 2008

Muzz Haniffa PhD, 2008

Ross Flockhart PhD, 2007*

Simon Meggitt MD with distinction, 2006*

Philip Hampton PhD, 2006*

Sandy McBride MD with commendation, 2002*

Wael Al-Daraji MD, 2002*

Paula Fearon PhD, 2002*

*Primary supervisor

NIHR Clinical Academic Training - Current

Zarif Jabbar-Lopez, Academic Clinical Fellow

Henry Grantham, Academic Foundation Fellow

Robert Samuel,  Academic Foundation Fellow



British Society for Rheumatology , Glasgow: “Newer therapeutic agents for psoriasis: a dermatological perspective

Psoriasis Association AGM, Northampton: “Psoriasis Stratification to Optimise Relevant Therapy (PSORT)”.

European Association for Dermato-Venereology (EADV) Fostering Course, Rotterdam, The Netherlands: “How to run a clinical trial”.

British Association of Dermatologists (BAD) Annual meeting, Birmingham Derm School: Translational Dermatology


BSID, Southampton, UK: UK TREND  - an opportunity for research

World Congress of Dermatology, Vancouver, Canada: A systems biology approach to understanding the mechanism of action of UVB phototherapy in psoriasis

World Congress of Dermatology, Vancouver, Canada: Systems dermatology: insights into epidermal remodeling in psoriasis

BAD Annual Meeting, Manchester, UK: Research across the academic industrial interface

BAD Annual Meeting, Manchester, UK: Engaging with UK Translational Research Network in Dermatology

European Dermatoepidemiology Network, ESDR, Rotterdam, Netherlands: Personalised Medicine for Skin Diseases

EADV Annual Meeting, Copenhagen, Denmark: A critical appraisal of biologics for psoriasis

Real World Evidence Conference (Janssen), London, UK:  BADBIR and PSORT: a pharmacovigilance registry leading onto a stratified medicine initiative

‘Allergy & the Skin’ Study Day, London, UK How should we manage patients with difficult atopic eczema


EADV Annual Meeting, Amsterdam, The Netherlands: “Personalised medicine for inflammatory skin disease”

BAD Annual Meeting, Glasgow, UK: “Physiology and importance of IL-17 in the pathogenesis of psoriasis”

ESDR/EADV Summer Research School, Helsinki, Finland: “Cutaneous transcriptomics”

RCP of Edinburgh Symposium on Dermatology: “How should we manage patients with difficult eczema?”

KSID, Seoul, South Korea: “Mechanistic insight into epidermal remodelling in psoriasis: a systems biology approach”


Leo Research Foundation Prize Award Ceremony, Copenhagen, Denmark: “The dynamic platform of translational research: from bench to bedside and back again”

ESDR Future Leaders Academy, Florence, Italy, A journey through Translation

Medicine and me symposium, RSM, London: “Key advances in psoriasis research”

EADV meeting, Istanbul: “Keratinocyte apoptosis in remodeling and clearance of psoriatic plaques” and “Efficacy of phototherapy in childhood and adult atopic eczema”

BAD Annual Meeting, Liverpool: “Future psoriasis therapy beyond TNF-a blockade” and “Systemic treatment for severe adult atopic dermatitis”

Psoriasis International Network Congress, Paris: “Resistant palmoplantar pustulosis” and “The impact and management of psoriasis in pregnancy”

Irish Association of Dermatologists Meeting, Belfast

RSM Michael Fuell Memorial Lecture, London: “Systems biology in dermatology: mechanistic insight into epidermal remodelling in psoriasis”